Charting The Changing Landscape in Multiple Myeloma from Frontline to Relapsed/Refractory Disease
View More
Cases and Conversations™: Nursing Considerations for the Management of ER+ Breast Cancer
View More
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
View More
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
ACCC 40th National Oncology Conference Pre-Session: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward
Register Now!
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
September 25th 2023The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
First-line treatment with lutetium Lu 177 dotatate plus long-acting octreotide led to a statistically significant and clinically meaningful improvement in progression-free survival compared with high-dose long-acting octreotide alone in newly diagnosed patients with somatostatin receptor–positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors.
Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides
September 25th 2023A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma, a form of kidney cancer, using image processing with deep learning.
Physicians Must Become Advocates to Play a Role in Community Oncology’s Future
September 25th 2023Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer
September 24th 2023Ezra Rosen, MD, PhD, highlights the early-phase investigation of zotatifin in estrogen receptor-positive metastatic breast cancer, explains the agent’s unique mechanism of action as well as its efficacy and safety in a heavily pretreated population, and underscores the need for improved sequencing of the myriad of treatment options in the post–CDK4/6 inhibitor space.
Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC
Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer
European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma
September 22nd 2023The European Commission has granted marketing authorization for Rylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month and older who developed hypersensitivity or silent inactivation to E. coli–derived asparaginase.
Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC
The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated.
Treatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer who were eligible for cisplatin- or carboplatin-containing chemotherapy.
Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC
Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy, followed by surgery and adjuvant nivolumab monotherapy, generated a statistically significant and clinically meaningful improvement in event-free survival vs neoadjuvant chemotherapy plus placebo, followed by surgery and adjuvant placebo, in patients with resectable stage IIA to IIIB non–small cell lung cancer.
Novel Targets Could Expand CAR T-Cell Therapy and Bispecific Antibody Options in Myeloma
Ajai Chari, MD, discusses selecting between CAR T-cell therapies and bispecific antibodies in multiple myeloma, expands on the factors that can help inform these decisions, and highlights the need for additional data to help inform sequencing and potential combinations for these therapies.
Continued CRC Research Informs Later-Line Disease Management
September 21st 2023Howard S. Hochster, MD, highlights key updates in CRC research and management from the 2023 ASCO Annual Meeting, including findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study.
Ifinatamab Deruxtecan Demonstrates Robust Efficacy, Acceptable Safety in SCLC
September 21st 2023Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.
Multiple Myeloma: The Black Community, Disparities & Clinical Trials
September 21st 2023The incidence of multiple myeloma, a rare and incurable cancer of a person’s plasma cells that fight infection and disease, is more than two times higher in Black people compared to white people according to the American Cancer Society’s 2022-2024 Cancer Facts & Figures for African American/Black People.
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
September 21st 2023Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera
The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia
September 21st 2023Uwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s investigation in patients with lower-risk MDS who are transfusion independent.
Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.
FCR Retains Curative Potential in Young Patients With Favorable CLL Biology
September 20th 2023John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.